<p>Quadrant Private Wealth Management LLC 在最近向证券交易委员会（SEC）提交的文件中披露，其在辉瑞公司（NYSE:PFE - 免费报告）的持股在第二季度减少了 10.1%。该公司在季度内出售了 12,001 股后，持有 106,984 股生物制药公司的股票。截至其最近的 SEC 文件，Quadrant Private Wealth Management LLC 在辉瑞的持股价值为 2,593,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 10/06 - 10/10</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对该股票的持股。Capital Advisory Group Advisory Services LLC 在第二季度将其在辉瑞的股份增加了 2.9%。Capital Advisory Group Advisory Services LLC 目前持有 13,542 股生物制药公司的股票，价值 328,000 美元，此前在上个季度增持了 388 股。Citizens National Bank Trust Department 在第二季度将其在辉瑞的持股增加了 0.9%。Citizens National Bank Trust Department 目前持有 46,103 股生物制药公司的股票，价值 1,118,000 美元，此前在上个季度增持了 395 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股增加了 2.0%。Able Wealth Management LLC 目前持有 21,128 股生物制药公司的股票，价值 512,000 美元，此前在上个季度增持了 413 股。Trust Co of the South 在第二季度将其在辉瑞的持股增加了 1.5%。Trust Co of the South 目前持有 29,386 股生物制药公司的股票，价值 712,000 美元，此前在上个季度增持了 441 股。最后，Charter Oak Capital Management LLC 在第二季度将其在辉瑞的持股增加了 4.3%。Charter Oak Capital Management LLC 目前持有 10,663 股生物制药公司的股票，价值 258,000 美元，此前在上个季度增持了 444 股。机构投资者持有该公司 68.36% 的股票。</p>
<h2>辉瑞价格表现</h2>
<p>辉瑞（PFE）股票周五开盘价为 24.45 美元。该公司的市值为 1389.9 亿美元，市盈率为 13.00，市盈率/增长比率为 0.81，贝塔值为 0.54。该公司的 50 日简单移动平均线为 24.74 美元，200 日简单移动平均线为 24.35 美元。辉瑞公司的一年最低价为 20.92 美元，一年最高价为 27.69 美元。该公司的债务与股本比率为 0.65，流动比率为 1.16，速动比率为 0.85。</p>
<ul>
<li>5 个推动医疗行业大反弹的股票</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 11 月 4 日（星期二）公布了季度财报。该生物制药公司报告每股收益（EPS）为 0.87 美元，超出分析师一致预期的 0.79 美元，超出幅度为 0.08 美元。该公司在季度内的收入为 166.5 亿美元，而分析师预期为 169.4 亿美元。辉瑞的股本回报率为 21.42%，净利润率为 16.84%。辉瑞已将 2025 财年的指引设定为 3.000-3.150 EPS。整体来看，股票分析师预计辉瑞公司今年将发布 2.95 EPS。</p>
<h2>辉瑞宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 12 月 1 日（星期一）支付。11 月 7 日（星期五）登记的投资者将获得 0.43 美元的分红。该分红的除息日为 11 月 7 日（星期五）。这代表着年化分红为 1.72 美元，收益率为 7.0%。辉瑞的分红支付比率为 100.00%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
<p>多家券商最近对 PFE 发表了评论。摩根士丹利将辉瑞的目标价从 33.00 美元下调至 32.00 美元，并在 10 月 10 日（星期五）的研究报告中对该公司给予了 “持平” 评级。高盛集团重申了 “中性” 评级，并在周三对辉瑞的股票设定了 26.00 美元的目标价。Sanford C. Bernstein 在 10 月 31 日（星期五）的报告中重新发布了 “市场表现” 评级，并对辉瑞的股票设定了 30.00 美元的目标价。瑞银集团在 10 月 1 日（星期三）的研究报告中重申了 “中性” 评级，并对辉瑞的股票设定了 28.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对辉瑞股票的 “持有（c-）” 评级。一位股票研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 28.18 美元。</p>
<p><strong>查看我们最新的辉瑞股票分析</strong></p>
<h2>辉瑞简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过辉瑞</li>
<li>如何从成长投资中获利</li>
<li>OpenAI 的重组为可能成为最大 IPO 铺平了道路</li>
<li>投资者如何从盘后交易中受益</li>
<li>2 只美国政府不希望失败的稀土股票</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
<p><strong>想知道其他对 PFE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Quadrant Private Wealth Management LLC 在第二季度减少了对辉瑞公司（NYSE:PFE）10.1% 的持股，出售了 12,001 股，剩余 106,984 股，市值为 2,593,000 美元。其他机构投资者也调整了他们的持股。辉瑞的股票开盘价为 24.45 美元，市值为 1,389.9 亿美元。该公司报告第三季度每股收益为 0.87 美元，超出预期，并宣布季度股息为 0.43 美元，收益率为 7.0%。分析师对辉瑞的评级不一，目标价格范围在 26.00 美元到 33.00 美元之间</p>

<p>Quadrant Private Wealth Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 10.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,984 shares of the biopharmaceutical company's stock after selling 12,001 shares during the quarter. Quadrant Private Wealth Management LLC's holdings in Pfizer were worth $2,593,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Quadrant Private Wealth Management LLC 在最近向证券交易委员会（SEC）提交的文件中披露，其在辉瑞公司（NYSE:PFE - 免费报告）的持股在第二季度减少了 10.1%。该公司在季度内出售了 12,001 股后，持有 106,984 股生物制药公司的股票。截至其最近的 SEC 文件，Quadrant Private Wealth Management LLC 在辉瑞的持股价值为 2,593,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/06 - 10/10</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 10/06 - 10/10</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Capital Advisory Group Advisory Services LLC grew its stake in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares during the last quarter. Able Wealth Management LLC grew its position in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Trust Co of the South grew its position in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Finally, Charter Oak Capital Management LLC increased its holdings in shares of Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after purchasing an additional 444 shares during the last quarter. Institutional investors own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对该股票的持股。Capital Advisory Group Advisory Services LLC 在第二季度将其在辉瑞的股份增加了 2.9%。Capital Advisory Group Advisory Services LLC 目前持有 13,542 股生物制药公司的股票，价值 328,000 美元，此前在上个季度增持了 388 股。Citizens National Bank Trust Department 在第二季度将其在辉瑞的持股增加了 0.9%。Citizens National Bank Trust Department 目前持有 46,103 股生物制药公司的股票，价值 1,118,000 美元，此前在上个季度增持了 395 股。Able Wealth Management LLC 在第二季度将其在辉瑞的持股增加了 2.0%。Able Wealth Management LLC 目前持有 21,128 股生物制药公司的股票，价值 512,000 美元，此前在上个季度增持了 413 股。Trust Co of the South 在第二季度将其在辉瑞的持股增加了 1.5%。Trust Co of the South 目前持有 29,386 股生物制药公司的股票，价值 712,000 美元，此前在上个季度增持了 441 股。最后，Charter Oak Capital Management LLC 在第二季度将其在辉瑞的持股增加了 4.3%。Charter Oak Capital Management LLC 目前持有 10,663 股生物制药公司的股票，价值 258,000 美元，此前在上个季度增持了 444 股。机构投资者持有该公司 68.36% 的股票。</p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>辉瑞价格表现</h2>
</div><p>Shares of PFE stock opened at $24.45 on Friday. The company has a market capitalization of $138.99 billion, a P/E ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54. The company's 50-day simple moving average is $24.74 and its two-hundred day simple moving average is $24.35. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.</p>
<div class="lb-trans"><p>辉瑞（PFE）股票周五开盘价为 24.45 美元。该公司的市值为 1389.9 亿美元，市盈率为 13.00，市盈率/增长比率为 0.81，贝塔值为 0.54。该公司的 50 日简单移动平均线为 24.74 美元，200 日简单移动平均线为 24.35 美元。辉瑞公司的一年最低价为 20.92 美元，一年最高价为 27.69 美元。该公司的债务与股本比率为 0.65，流动比率为 1.16，速动比率为 0.85。</p>
</div><ul>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个推动医疗行业大反弹的股票</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 11 月 4 日（星期二）公布了季度财报。该生物制药公司报告每股收益（EPS）为 0.87 美元，超出分析师一致预期的 0.79 美元，超出幅度为 0.08 美元。该公司在季度内的收入为 166.5 亿美元，而分析师预期为 169.4 亿美元。辉瑞的股本回报率为 21.42%，净利润率为 16.84%。辉瑞已将 2025 财年的指引设定为 3.000-3.150 EPS。整体来看，股票分析师预计辉瑞公司今年将发布 2.95 EPS。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer's dividend payout ratio is 100.00%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 12 月 1 日（星期一）支付。11 月 7 日（星期五）登记的投资者将获得 0.43 美元的分红。该分红的除息日为 11 月 7 日（星期五）。这代表着年化分红为 1.72 美元，收益率为 7.0%。辉瑞的分红支付比率为 100.00%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 AbbVie 和强生可能会超越辉瑞</li>
</ul>
</div><p>A number of brokerages recently commented on PFE. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday, October 10th. The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday. Sanford C. Bernstein reissued a &#34;market perform&#34; rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. UBS Group restated a &#34;neutral&#34; rating and issued a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of Pfizer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $28.18.</p>
<div class="lb-trans"><p>多家券商最近对 PFE 发表了评论。摩根士丹利将辉瑞的目标价从 33.00 美元下调至 32.00 美元，并在 10 月 10 日（星期五）的研究报告中对该公司给予了 “持平” 评级。高盛集团重申了 “中性” 评级，并在周三对辉瑞的股票设定了 26.00 美元的目标价。Sanford C. Bernstein 在 10 月 31 日（星期五）的报告中重新发布了 “市场表现” 评级，并对辉瑞的股票设定了 30.00 美元的目标价。瑞银集团在 10 月 1 日（星期三）的研究报告中重申了 “中性” 评级，并对辉瑞的股票设定了 28.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对辉瑞股票的 “持有（c-）” 评级。一位股票研究分析师对该股票给予了强烈买入评级，四位给予了买入评级，十二位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 28.18 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的辉瑞股票分析</strong></p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>辉瑞简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来潜在的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How to Profit From Growth Investing</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过辉瑞</li>
<li>如何从成长投资中获利</li>
<li>OpenAI 的重组为可能成为最大 IPO 铺平了道路</li>
<li>投资者如何从盘后交易中受益</li>
<li>2 只美国政府不希望失败的稀土股票</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 PFE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Quadrant Private Wealth Management LLC Sells 12,001 Shares of Pfizer Inc. $PFE

- Quadrant Private Wealth Management LLC 在第二季度减持了 10.1% 的 Pfizer 持股。  
- 该公司目前持有 106,984 股，市值约为 2,593,000 美元。  
- Pfizer 最近公布的季度每股收益为 0.87 美元，超出预期。  

Quadrant 私人财富管理有限责任公司出售了辉瑞公司 12,001 股股票